In order to further strengthen its oncology pipeline, Gilead has agreed to acquire Tubulis for up to US$5 B, including US$3.15 B upfront and up to US$1.85 B in continent milestone payments. Through the deal, Gilead picks up access to TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i) antibody-drug conjugate (ADC) for platinum-resistant ovarian cancer and non-small cell lung cancer as well as TUB-030, a 5T4 targeted ADC for various solid tumours. The deal marks one of Gilead’s largest ADC-focused deals since its US$21 B purchase of Immunomedics in 2020.